:: 13 Nov 2008 ::
Patents Issue for Inotek Pharmaceuticals’ Lead Clinical Candidates in Glaucoma and Contrast-Induced Nephropathy
:: read full press release ::

:: 1 Oct 2008 ::
Inotek Appoints Paul G. Howes as President and CEO
:: read full press release ::

:: 18 Jun 2008 ::
Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist
:: read full press release ::

:: 8 Apr 2008 ::
Inotek Focuses Resources on Clinical Programs, Adds to Executive Management Team and Consolidates Operations in Massachusetts
:: read full press release ::

:: 23 Aug 2007 ::
Inotek Pharmaceuticals Secures $19 million Financing
:: read full press release ::

:: 10 Apr 2007 ::
Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke
:: read full press release ::

:: 27 Mar 2007 ::
Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
:: read full press release ::

:: 14 Feb 2007 ::
Inotek Pharmaceuticals Announces Additions to its Board of Directors
:: read full press release ::

:: 3 Jan 2007 ::
Inotek Pharmaceuticals to Present at the 25th Annual JP Morgan Healthcare Conference
:: read full press release ::

:: 25 Jul 2006 ::
Genentech & Inotek enter into Exclusive Global Strategic Alliance for the Discovery, Development, and Commercialization of PARP Inhibitors for Cancer
:: read full press release ::